CTOs on the Move

Ideaya Biosciences

www.ideayabio.com

 
IDEAYA Biosciences is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. Founded in 2015, IDEAYA`s investors include 5AM Ventures (5AM), Canaan Partners (Canaan), Celgene, WuXi Healthcare Ventures (WuXi), Novartis Institute of Biomedical Research, and Alexandria Real Estate. The Company has assembled a world-class drug discovery team and Scientific Advisory Board (SAB) that is represented by a Nobel Laureate and three Members of the National Academy of Sciences. IDEAYA is located in South San Francisco and La Jolla, California.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.ideayabio.com
  • 7000 Shoreline Court Suite 350
    South San Francisco, CA USA 94080
  • Phone: 650.443.6209

Executives

Name Title Contact Details
Solomon Wang
Director, IT Profile

Funding

Ideaya Biosciences raised $94M on 03/15/2018
Ideaya Biosciences raised $86.1M on 07/07/2021

Similar Companies

Conagen

Conagen is a #syntheticbiology leader, supporting our global partners through #enzymatic and #microbial platforms and #biomanufacturing capabilities.

CollabRx

CollabRx is a clinical decision-support company delivering expert solutions in precision oncology that enable physicians, laboratories, payers, and providers to achieve standardized, evidence-based care and superior clinical outcomes. CollabRx uses information technology to aggregate and contextualize the world`s knowledge on genomics-based medicine with specific insights from the nation`s top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care.

Advanced Research Projects Agency for Health

The Advanced Research Projects Agency for Health (ARPA-H) is committed to solving the most challenging problems in health by developing research programs dedicated to urgency, excellence and honesty. Part of the U.S. Department of Health and Human Services, ARPA-H aims to accelerate breakthroughs that empower every American to realize their full health potential – turning the seemingly impossible to the possible to the actual. The ARPA model is a continuous cycle of planning, implementing, and evaluating, and we`re looking for the best ideas and the brightest minds to carry out each process. We`re committed to diversity in all its forms.

HemoShear Therapeutics

We are dedicated to discovering novel biological targets and developing drugs that profoundly improve the lives of people born with rare metabolic defects who are unable to sustain basic biochemical processes necessary for life.

onramp 113

onramp 113 is a Dixon, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.